

Applicant : Nariyoshi Shinomiya et al.
Appln. No. : 10/599,327
Page : 2

Amendments to Claims

In the Claims:

Prior to further examination of this application, please amend the claims as shown below.

1. *(Canceled)*
2. *(Previously presented)* The RNAi molecule of claim 4 that is a single stranded siRNA that forms a hairpin structure.
3. *(Previously presented)* The RNAi molecule of claim 4 that is a double stranded siRNA.
4. *(Currently amended)* An interfering RNA (RNAi) molecule that comprises SEQ ID NO:15, wherein the RNAi is between about 19 and about 29 nucleotides in length.
- 5-7. *(Canceled)*
8. *(Previously presented)* A DNA molecule encoding the RNAi molecule of claim 4.
9. *(Previously presented)* An expression construct comprising DNA that encodes the RNAi molecule of claim 4 operatively linked to a promoter that drives the expression of said RNAi molecule in a *c-met*-expressing cell.
10. *(Original)* An expression construct comprising the DNA molecule of claim 8.

Applicant : Nariyoshi Shinomiya et al.
Appln. No. : 10/599,327
Page : 3

11. (*Currently amended*) The expression construct of claim 9, wherein ~~[[a]]~~ the promoter ~~is~~
~~one that~~ drives the expression of said RNAi molecule in a c-met-expressing tumor or cancer cell.

12. (*Previously presented*) The expression construct of claim 11 wherein the promoter is a polIII promoter.

13. (*Original*) The expression construct of claim 12 wherein the polIII promoter is a U6 promoter.

14. (*Previously presented*) A viral vector comprising the expression construct of claim 9.

15. (*Original*) The viral vector of claim 14 that is a transient expression vector.

16. (*Previously presented*) The viral vector of claim 14 that is a stable expression vector.

17. (*Previously presented*) The viral vector of claim 14 that is an adenoviral vector.

18. (*Original*) The adenoviral vector of claim 17 that is an Ad5 viral vector.

19-37. (*Canceled*)

Applicant : Nariyoshi Shinomiya et al.
Appln. No. : 10/599,327
Page : 4

38. (*Previously presented*) A method of treating a c-*met*⁺ tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 14 effective for inhibiting expression of c-*met* and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

39-47. (*Canceled*)

48. (*Previously presented*) The method of claim 38 wherein the tumor or cancer is glioblastoma, prostate or gastric.

49. (*Previously presented*) A method of treating a c-*met*⁺ tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 19 effective for inhibiting expression of c-*met* and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

50. (*Previously presented*) The method of claim 49 wherein the tumor or cancer is glioblastoma, prostate or gastric.